Literature DB >> 11505142

Activation of alveolar macrophages in acid-injured lung in rats: different effects of pentoxifylline on tumor necrosis factor-alpha and nitric oxide production.

I Kudoh1, H Miyazaki, M Ohara, J Fukushima, T Tazawa, H Yamada.   

Abstract

OBJECTIVE: To determine whether acid instillation augments tumor necrosis factor-alpha and nitric oxide production by alveolar macrophages in rats, and to study the effects of treatment with pentoxifylline before acid instillation on the production of these inflammatory mediators.
DESIGN: Controlled laboratory investigation on tumor necrosis factor-alpha and nitric oxide production by alveolar macrophages of rats that had acid-induced lung injury.
SETTING: University research laboratory. SUBJECT: Alveolar macrophages of rats.
INTERVENTIONS: Alveolar macrophages were recovered by bronchoalveolar lavage at 4, 10, 16, 24, and 72 hrs after unilateral hydrochloric acid (pH, 1.0; volume, 0.1 mL) instillation into the lungs of rats. Alveolar macrophages then were cultured with or without lipopolysaccharide. One group of rats was pretreated with pentoxifylline before acid instillation.
MEASUREMENTS AND MAIN RESULTS: Alveolar macrophages from both acid-instilled and contralateral lungs, which had recovered 24 hrs after acid instillation, produced significantly greater tumor necrosis factor-alpha and nitric oxide. Subsequent exposure to lipopolysaccharide, as a surrogate for bacterial infection, further promoted tumor necrosis factor-alpha and nitric oxide release. Alveolar macrophages from rats pretreated with pentoxifylline before acid instillation produced significantly less tumor necrosis factor-alpha and did not overproduce tumor necrosis factor-alpha when exposed to lipopolysaccharide. In contrast, pretreatment with pentoxifylline had no effect on nitric oxide production by alveolar macrophages.
CONCLUSIONS: Acid instillation stimulates alveolar macrophages to produce tumor necrosis factor-alpha and nitric oxide. Pentoxifylline preserved innate production of tumor necrosis factor-alpha to lipopolysaccharide and did not inhibit the production of bactericidal nitric oxide. This may partly explain why pentoxifylline reduces acid aspiration-induced lung injury while maintaining the host's ability to combat bacterial infection after acid aspiration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505142     DOI: 10.1097/00003246-200108000-00020

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  5 in total

1.  The effect of hyperbaric oxygen treatment on aspiration pneumonia.

Authors:  Sevtap Hekimoglu Sahin; Mehmet Kanter; Suleyman Ayvaz; Alkin Colak; Burhan Aksu; Ahmet Guzel; Umit Nusret Basaran; Mustafa Erboga; Ali Ozcan
Journal:  J Mol Histol       Date:  2011-06-08       Impact factor: 2.611

2.  Akt2 deficiency as a therapeutic strategy protects against acute lung injury.

Authors:  Adrienne E Gauna; Seunghee Cha
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

3.  Hydrochloric acid-induced lung injury: effects of early partial liquid ventilation on survival rate, gas exchange, and pulmonary neutrophil accumulation.

Authors:  Michael A Pakulla; David Seidel; Detlef Obal; Stephan A Loer
Journal:  Intensive Care Med       Date:  2004-09-21       Impact factor: 17.440

4.  Preventive effects of curcumin on different aspiration material-induced lung injury in rats.

Authors:  Ahmet Guzel; Mehmet Kanter; Burhan Aksu; Umit Nusret Basaran; Omer Yalçin; Aygul Guzel; Hafise Uzun; Dildar Konukoğlu; Serap Karasalihoglu
Journal:  Pediatr Surg Int       Date:  2008-11-12       Impact factor: 1.827

5.  Effects of pentoxifylline on TNF-alpha and lung histopathology in HCL-induced lung injury.

Authors:  Itamar Souza Oliveira-Júnior; Itamar Souza de Oliveira-Júnior; Carla Cristina Maganhin; Adriana Aparecida Ferraz Carbonel; Cristina Maria Rodrigues Monteiro; Sâmia Santos Cavassani; Ricardo Martins Oliveira-Filho
Journal:  Clinics (Sao Paulo)       Date:  2008-02       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.